NICE has recommended Nanox.AI’s HealthOST and HealthVCF for Early Value Assessment, enabling NHS hospitals to deploy the AI tools for three years while gathering evidence on their value in detecting vertebral fragility fractures. The decision marks an important step in advancing AI-driven early detection of osteoporosis.
CMS has finalized two separate 2026 rulings benefiting neuromodulation innovators: stable outpatient reimbursement for Magnus Medical’s SAINT therapy and significant payment increases for NeuroPace’s RNS System across physician and hospital settings. The updates strengthen patient access and support broader adoption of advanced brain-health technologies.
ConcertAI’s TeraRecon division has launched DETECT, an AI-first platform designed to close the gap between imaging innovation and reimbursement.
Germany issued two significant regulatory updates: the G-BA expanded its emergency-care tier system by adding a new “non-participation” level, and IQWiG reported that daratumumab shows no proven survival benefit in smoldering multiple myeloma due to flaws in the comparator arm of the AQUILA study.
CMS has set national pricing for the inFlow Voiding Prosthesis in the 2026 Medicare fee schedule, expanding access to the only alternative to lifelong catheter use for women with permanent urinary retention.
NICE has published three updates spanning diagnostics, acute care, and oncology: conditional support for AI tools that detect bowel cancer polyps, new sepsis guidelines emphasizing tailored treatment, and the termination of a trastuzumab deruxtecan appraisal after no company evidence submission.
Minnesota applied for $1B under the federal Rural Health Transformation Program to strengthen rural hospitals, telehealth, and workforce capacity.
IQWiG has concluded that darolutamide offers no proven added benefit over apalutamide for metastatic hormone-sensitive prostate cancer.
CMS Sets 2026 Medicare Premiums and Deductibles as Cost Pressures Mount and Regulatory Fixes Temper Increases The Centers for Medicare & Medicaid Services (CMS) has released the 2026 Medicare Parts A and B premiums, deductibles, and income-related adjustment amounts, outlining another year of steady cost increases across the program. While the updates reflect predictable inflationary … Read more
NICE has issued three major recommendations expanding access to Columvi-GemOx for DLBCL, talquetamab for relapsed myeloma, and delgocitinib for chronic hand eczema.